Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report
- PMID: 34352279
- DOI: 10.1016/j.chest.2021.07.056
Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report
Abstract
Background: This is the 2nd update to the 9th edition of these guidelines. We provide recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions, four of which have not been addressed previously.
Methods: We generate strong and weak recommendations based on high-, moderate-, and low-certainty evidence, using GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology.
Results: The panel generated 29 guidance statements, 13 of which are graded as strong recommendations, covering aspects of antithrombotic management of VTE from initial management through secondary prevention and risk reduction of postthrombotic syndrome. Four new guidance statements have been added that did not appear in the 9th edition (2012) or 1st update (2016). Eight statements have been substantially modified from the 1st update.
Conclusion: New evidence has emerged since 2016 that further informs the standard of care for patients with VTE. Substantial uncertainty remains regarding important management questions, particularly in limited disease and special patient populations.
Keywords: DVT; antithrombotic therapy; guidelines; pulmonary embolism; thrombosis.
Copyright © 2021. Published by Elsevier Inc.
Similar articles
-
Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.Chest. 2021 Dec;160(6):e545-e608. doi: 10.1016/j.chest.2021.07.055. Epub 2021 Aug 2. Chest. 2021. PMID: 34352278
-
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest. 2008 Jun;133(6 Suppl):454S-545S. doi: 10.1378/chest.08-0658. Chest. 2008. PMID: 18574272
-
Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl):e419S-e496S. doi: 10.1378/chest.11-2301. Chest. 2012. PMID: 22315268 Free PMC article.
-
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest. 2004 Sep;126(3 Suppl):401S-428S. doi: 10.1378/chest.126.3_suppl.401S. Chest. 2004. PMID: 15383479 Review.
-
Antithrombotic Therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012-2021.Chest. 2024 Aug;166(2):388-404. doi: 10.1016/j.chest.2024.03.003. Epub 2024 Mar 6. Chest. 2024. PMID: 38458430 Review.
Cited by
-
Real-world data on direct oral anticoagulants in BCR::ABL1-negative myeloproliferative neoplasms (MPNs): a multicenter retrospective study on behalf of scientific subcommittee on MPNs for Turkish society of hematology.J Thromb Thrombolysis. 2024 Nov 11. doi: 10.1007/s11239-024-03043-5. Online ahead of print. J Thromb Thrombolysis. 2024. PMID: 39527392
-
Rivaroxaban for Thromboembolism Prophylaxis in Patients with Nephrotic Syndrome: A Single-Arm, Prospective Study.Kidney Dis (Basel). 2024 Aug 16;10(5):346-358. doi: 10.1159/000540107. eCollection 2024 Oct. Kidney Dis (Basel). 2024. PMID: 39430289 Free PMC article.
-
The Incidence of Thrombotic Events After the Concomitant Use of Andexanet alfa and 4-Factor Prothrombin Complex Concentrate.Hosp Pharm. 2024 Oct;59(5):536-543. doi: 10.1177/00185787241242759. Epub 2024 Mar 29. Hosp Pharm. 2024. PMID: 39318740
-
Direct Oral Anticoagulants in Antiphospholipid Syndrome-Associated Venous Thromboembolism: Real World Evidence.J Korean Med Sci. 2024 Sep 23;39(36):e252. doi: 10.3346/jkms.2024.39.e252. J Korean Med Sci. 2024. PMID: 39315443 Free PMC article.
-
Safety and Effectiveness of Direct Oral Anticoagulants Versus Warfarin in Patients with Venous Thromboembolism using Real-World Data: A Systematic Review and Meta-Analysis.Am J Cardiovasc Drugs. 2024 Nov;24(6):823-839. doi: 10.1007/s40256-024-00677-x. Epub 2024 Sep 10. Am J Cardiovasc Drugs. 2024. PMID: 39254826
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
